Then, IRF9 is a known regulator of PAH chronic inflammation and innate immune responses to viral infections, while LINC01089 has not been previously analyzed within PAH pathogenesis, though both are modulators of tumorigenic processes, suggesting their importance in PAH inflammatory phenotypes and the early stages of cancer. Here, IRF9 is linked to pulmonary arterial hypertension.